Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 4/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.40 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | SGK1 | O00141 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15882311 | 0.79 | ACLY (0.50) | ACLYMCL1HTR6FPR2PROKR1 | |
| SCHEMBL8199305 | 0.77 | ACLY (0.42) | ACLYMCL1HTR6FPR2PROKR1 | |
| SCHEMBL3956139 | 0.77 | ACLY (0.51) | ACLYMCL1HTR6FPR2PROKR1 | |
| SCHEMBL12932804 | 0.77 | MCL1 (0.49) | ACLYMCL1HTR6FPR2PROKR1 | |
| SCHEMBL16508903 | 0.75 | HTR6 (0.46) | ACLYMCL1HTR6FPR2PROKR1 | |
| SCHEMBL6097407 | 0.75 | MCL1 (0.45) | ACLYMCL1HTR6FPR2PROKR1 | |
| SCHEMBL1641772 | 0.74 | L3MBTL1 (0.43) | ACLYMCL1HTR6FPR2PROKR1 | |
| SCHEMBL388129 | 0.74 | L3MBTL1 (0.43) | ACLYMCL1HTR6FPR2PROKR1 | |
| SCHEMBL12878854 | 0.74 | MCL1 (0.43) | ACLYMCL1HTR6FPR2PROKR1 | |
| SCHEMBL12067166 | 0.73 | HTR6 (0.44) | ACLYMCL1HTR6FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023938-A1 | Sulfonamide derivatives | TABUCHI TAKANORI (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6586617-B1 | Nontoxic microbiocides such as 4'-chloro-N-ethyl-2'-nitro-p-toluenesulfonanilide, for agricultural or horticultural, prepared by alkylation or nitration | SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1174028-A1 | SULFONAMIDE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023938-A1 | Sulfonamide derivatives | FPR1, MRM1, SULT1E1 | ACLY 842/4885MCL1 872/4885HTR6 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.